Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

New Pediatric Labeling Information Database - Detail
  • Print
  • Share
  • E-mail
-
 
Pediatric Labeling Date:  09/02/2009
 
Trade Name:  Intuniv
 
Generic Name or Proper Name (*):  guanfacine
 
Indications Studied:  ADHD
 
Label Changes Summary:  Efficacy established in 2 controlled clinical trials in children 6-17 years Safety and efficacy in pediatric patients< 6 years have not been established In clinical trials, there were dose and exposure-related risks for adverse events (AEs) including hypotension, bradycardia, and sedative events. Somnolence and sedation were reported in 38% on guanfacine vs. 12% on placebo in children and adolescents with ADHD, especially during initial use Information on dosing, clinical trials, and AEs New dosage form
 
Product Labeling:  Labeling  Opens a new window
 
PREA(P):  P
 
Sponsor:  Shire
 
NNPS:  FALSE'
 
Therapeutic Category:  Non-stimulant ADHD treatment
 
-
-